[go: up one dir, main page]

FR22C1064I1 - Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins - Google Patents

Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins

Info

Publication number
FR22C1064I1
FR22C1064I1 FR22C1064C FR22C1064C FR22C1064I1 FR 22C1064 I1 FR22C1064 I1 FR 22C1064I1 FR 22C1064 C FR22C1064 C FR 22C1064C FR 22C1064 C FR22C1064 C FR 22C1064C FR 22C1064 I1 FR22C1064 I1 FR 22C1064I1
Authority
FR
France
Prior art keywords
vaccines
compositions
methods
dengue virus
constructions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1064C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Government of the United States of America
Original Assignee
Takeda Vaccines Inc
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, Government of the United States of America filed Critical Takeda Vaccines Inc
Publication of FR22C1064I1 publication Critical patent/FR22C1064I1/fr
Application granted granted Critical
Publication of FR22C1064I2 publication Critical patent/FR22C1064I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1064C 2013-03-15 2022-12-16 Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins Active FR22C1064I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
PCT/US2014/024603 WO2014150939A2 (fr) 2013-03-15 2014-03-12 Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins
EP14722014.9A EP2968516B1 (fr) 2013-03-15 2014-03-12 Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins

Publications (2)

Publication Number Publication Date
FR22C1064I1 true FR22C1064I1 (fr) 2023-02-03
FR22C1064I2 FR22C1064I2 (fr) 2024-12-13

Family

ID=50678274

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1064C Active FR22C1064I2 (fr) 2013-03-15 2022-12-16 Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins

Country Status (32)

Country Link
US (6) US9783579B2 (fr)
EP (5) EP4183411A1 (fr)
JP (2) JP6818548B2 (fr)
KR (4) KR102626270B1 (fr)
CN (5) CN113637693B (fr)
AR (4) AR095598A1 (fr)
AU (2) AU2014235476B2 (fr)
CA (3) CA3177574A1 (fr)
CR (1) CR20150569A (fr)
DK (1) DK4129330T5 (fr)
DO (1) DOP2015000232A (fr)
EC (1) ECSP23013715A (fr)
ES (2) ES2965652T3 (fr)
FI (2) FI3539565T3 (fr)
FR (1) FR22C1064I2 (fr)
HR (1) HRP20231581T1 (fr)
HU (2) HUE061507T2 (fr)
LT (2) LT4129330T (fr)
MX (5) MX374519B (fr)
MY (1) MY187796A (fr)
NL (1) NL301223I2 (fr)
NO (1) NO2023026I1 (fr)
NZ (1) NZ630869A (fr)
PE (2) PE20160027A1 (fr)
PH (1) PH12015502120B1 (fr)
PL (1) PL3539565T3 (fr)
PT (1) PT3539565T (fr)
SG (3) SG10201913387XA (fr)
SI (1) SI4129330T1 (fr)
TW (3) TWI894248B (fr)
UY (1) UY35489A (fr)
WO (1) WO2014150939A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231581T1 (hr) * 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
SG11201804317YA (en) * 2015-11-27 2018-06-28 The Chemo Sero Therapeutic Res Institute Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2021173597A1 (fr) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dosage multiplex rt-pcr spécifique du sérotype de la dengue
EP3892737A1 (fr) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Détermination qualitative et quantitative d'haplotypes de virus unique dans des échantillons complexes
WO2023147337A2 (fr) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Production et fabrication de vaccin à flavivirus à grande échelle
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (fr) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Détermination par ordinateur d'une infectivité de flavivirus
WO2024086681A1 (fr) * 2022-10-20 2024-04-25 Takeda Vaccines, Inc. Procédé de détection de la présence d'un sérotype du virus de la dengue dans un échantillon contenant au moins un sérotype du virus de la dengue
CN120225693A (zh) 2022-11-18 2025-06-27 武田疫苗股份有限公司 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025122855A1 (fr) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. Procédé pour déterminer la concentration de l'adn génomique résiduel des cellules vero dans un échantillon contenant un virus obtenu après production dans des cellules vero

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
CA2116980C (fr) 1991-09-19 2006-06-06 Ching-Juh Lai Flavivirus chimeriques et/ou a croissance restreinte
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
PT836482E (pt) 1995-05-24 2003-02-28 Hawaii Biotech Group Vacina subunitaria contra infeccao por flavirus
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
DK0977587T3 (da) 1997-02-28 2005-10-17 Acambis Inc Kimære flavivirus-vacciner
RU2208635C2 (ru) 1997-10-08 2003-07-20 ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
DE29810020U1 (de) 1998-06-04 1998-09-24 Siemens AG, 80333 München Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien
DE69934583T2 (de) 1998-06-04 2007-10-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
CA2398872C (fr) 2000-02-16 2018-03-20 Richard M. Kinney Flavivirus chimeriques avirulents et immunogenes
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
CA2440593A1 (fr) 2001-03-12 2002-09-19 Yale University Procedes et compositions comprenant des polypeptides du virus west nile
BRPI0613328A2 (pt) * 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
KR20080018271A (ko) * 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
LT2589602T (lt) * 2006-08-15 2016-10-10 The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health Dengė viruso vakcinos komponentų gavimas
US8541377B2 (en) 2007-07-13 2013-09-24 Florida Gulf Coast University Optimized dengue virus entry inhibitory peptide (DN81)
AU2009241354B2 (en) * 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
WO2010085358A2 (fr) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flavivirus exprimant le prm, e, et protéines de ns1 d'autres flavivirus, et utilisations afférentes
CN107913406A (zh) 2009-06-01 2018-04-17 武田疫苗公司 施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
NZ630831A (en) 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
KR20150036593A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
CA2933472A1 (fr) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, procedes d'administration et utilisations de formulations trivalentes contre le virus de la dengue
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (fr) 2015-07-03 2017-01-12 Sanofi Pasteur Vaccination simultanée contre la dengue, la diphtérie, le tétanos, la coqueluche (pertussis), la polio, et l'haemophilus influenzae de type b
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
US11007261B2 (en) 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7261239B2 (ja) 2017-10-16 2023-04-19 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生組換えフラビウイルスなどから成る安定したワクチン組成物およびその調製方法
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
EP3892737A1 (fr) 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Détermination qualitative et quantitative d'haplotypes de virus unique dans des échantillons complexes

Also Published As

Publication number Publication date
US12186363B2 (en) 2025-01-07
CA2903231A1 (fr) 2014-09-25
JP6818548B2 (ja) 2021-01-20
WO2014150939A3 (fr) 2014-12-31
KR20250033325A (ko) 2025-03-07
AU2019216724A1 (en) 2019-09-05
MY187796A (en) 2021-10-24
CN113637693B (zh) 2024-10-11
PE20160027A1 (es) 2016-01-28
US9783579B2 (en) 2017-10-10
NL301223I2 (nl) 2023-07-26
AU2019216724B2 (en) 2021-03-04
EP3539565B1 (fr) 2023-01-11
HUS2300022I1 (hu) 2023-08-28
SI4129330T1 (sl) 2024-02-29
NZ735336A (en) 2021-04-30
EP3539565A1 (fr) 2019-09-18
SG11201507460PA (en) 2015-10-29
KR20220054892A (ko) 2022-05-03
US20170290884A1 (en) 2017-10-12
PE20211814A1 (es) 2021-09-14
TWI733646B (zh) 2021-07-21
AU2019216724C1 (en) 2021-08-26
AR132009A2 (es) 2025-05-21
NZ630869A (en) 2017-11-24
CN105451763A (zh) 2016-03-30
NO2023026I1 (no) 2023-07-04
UY35489A (es) 2014-10-31
WO2014150939A2 (fr) 2014-09-25
EP4129330A1 (fr) 2023-02-08
CA3177572A1 (fr) 2014-09-25
CA3177574A1 (fr) 2014-09-25
BR122021015502A2 (pt) 2021-12-14
MX2023000349A (es) 2023-04-24
DK4129330T5 (da) 2024-07-22
MX2023000354A (es) 2023-02-13
LTPA2024503I1 (fr) 2024-03-25
CN105451763B (zh) 2021-06-18
LT4129330T (lt) 2023-12-27
JP7050031B2 (ja) 2022-04-07
TWI894248B (zh) 2025-08-21
CN113637086A (zh) 2021-11-12
CN111778263B (zh) 2024-07-26
KR20240014580A (ko) 2024-02-01
US20230181682A1 (en) 2023-06-15
TWI726312B (zh) 2021-05-01
ECSP23013715A (es) 2023-04-28
BR112015023635A2 (pt) 2018-06-05
CN113637694B (zh) 2024-11-12
KR102389908B1 (ko) 2022-04-26
PH12015502120A1 (en) 2016-01-25
EP4183411A1 (fr) 2023-05-24
CN113637693A (zh) 2021-11-12
KR20160002780A (ko) 2016-01-08
US20250018006A1 (en) 2025-01-16
BR122021015503A2 (pt) 2021-12-14
ES2933970T3 (es) 2023-02-15
EP3689374B1 (fr) 2022-11-02
EP3689374A1 (fr) 2020-08-05
HUE061507T2 (hu) 2023-07-28
MX2023000353A (es) 2023-02-13
US20140302088A1 (en) 2014-10-09
CA3166063A1 (fr) 2014-09-25
SG10201913435TA (en) 2020-03-30
JP2016513970A (ja) 2016-05-19
FIC20230021I1 (fi) 2023-06-27
FI3539565T3 (fi) 2023-04-19
EP2968516A2 (fr) 2016-01-20
AR133264A2 (es) 2025-09-10
KR102626270B1 (ko) 2024-01-19
CN113637694A (zh) 2021-11-12
EP2968516B1 (fr) 2022-01-12
KR102775714B1 (ko) 2025-03-06
HK1220359A1 (zh) 2017-05-05
CN111778263A (zh) 2020-10-16
AR123702A2 (es) 2023-01-04
PT3539565T (pt) 2023-04-12
FR22C1064I2 (fr) 2024-12-13
US20200061151A1 (en) 2020-02-27
US20220062375A1 (en) 2022-03-03
MX374519B (es) 2025-03-06
MX2019003602A (es) 2022-06-27
TW201516147A (zh) 2015-05-01
CR20150569A (es) 2016-04-01
CA2903231C (fr) 2025-12-09
TW201945545A (zh) 2019-12-01
AU2014235476B2 (en) 2019-05-16
EP4129330B1 (fr) 2023-09-06
AU2014235476A1 (en) 2015-09-24
MX2015012893A (es) 2016-04-04
CN113637086B (zh) 2024-10-11
AR095598A1 (es) 2015-10-28
TW202144573A (zh) 2021-12-01
HRP20231581T1 (hr) 2024-03-15
DK4129330T3 (da) 2023-12-11
JP2019146594A (ja) 2019-09-05
PH12015502120B1 (en) 2024-02-16
PL3539565T3 (pl) 2023-09-25
SG10201913387XA (en) 2020-02-27
US10449231B2 (en) 2019-10-22
BR112015023635A8 (pt) 2021-12-14
US11931399B2 (en) 2024-03-19
DOP2015000232A (es) 2016-02-29
ES2965652T3 (es) 2024-04-16

Similar Documents

Publication Publication Date Title
FR22C1064I1 (fr) Compositions et procédés pour constructions chimériques du virus de la dengue dans des vaccins
CY2021017I2 (el) Συνθεσεις irna toy pcsk9 και μεθοδοι χρησης αυτων
IL280819A (en) Adeno-associated virus virions with variant capsid and methods of use thereof
EP2834265A4 (fr) Procédés et compositions pour des épitopes du virus de la dengue
EP2699266A4 (fr) Compositions et procédés de stabilisation de principes actifs
IL236838B (en) Anti-dengue virus antibodies and uses thereof
ME03540B (fr) Compositions transdermiques d'ibuprofène et leurs méthodes d'utilisation
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
HUE038759T2 (hu) Terápiás nukleázkészítmények és eljárások
EP2804599A4 (fr) Compositions pharmaceutiques et procédés associés
EP2892315A4 (fr) Procédés et compositions réduisant le caractère hydrofuge des sols
BR112013014644A2 (pt) composição farmacêutica e complexo
EP2884984A4 (fr) Compositions et procédés thérapeutiques
EP2802362A4 (fr) Compositions de concentré de gel liquide et procédés d'utilisation
EP2800579A4 (fr) Procédés et compositions pour le traitement du diabète
EP2953962A4 (fr) Procédés de réduction des agrégats dans les préparations protéiniques
PL3400958T3 (pl) Kompozycje i metody leczenia celiakii
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
SG11201510617WA (en) Methods and compositions for dengue virus vaccines
EP2863939A4 (fr) Compositions et procédés pour le traitement du vitiligo
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
DK2646039T3 (da) Sammensætning og anvendelse deraf i behandlingen af analrhagader
EP2870238A4 (fr) Compositions et procédés associés à des vaccins viraux
EP2811295A4 (fr) Agent de séparation et son procédé de fabrication
EP2880186A4 (fr) Compositions et procédés pour améliorer le séquençage de nanopores